THYROID CANCERS

Lori Wirth, MD, discusses second-line treatment in relation to the patient case, and concludes the discussion with a look at emerging treatment options and the future of treating advanced RAI-refractory DTC.

An expert on thyroid cancer provides insights on treating patients with advanced RAI-refractory DTC who harbor BRAFV600E mutations.

Lori Wirth, MD, discusses molecular testing practices for patients with advanced RAI-refractory differentiated thyroid cancer.

A medical oncologist reviews real-world data on older patients with RAI-refractory DTC and provides her thoughts on treating this patient population.

An overview of the standard of care treatment for patients with advanced radioiodine-refractory differentiated thyroid cancer.

Lori Wirth, MD, discusses the safety profiles of sorafenib and lenvatinib and provides clinical insights on managing or mitigating adverse effects.

A medical oncologist provides a comprehensive overview of the current treatment options for patients with advanced RAI-refractory DTC and reviews clinical trial data on sorafenib and lenvatinib.

A leading expert on head and neck oncology provides her initial impressions on the case of a 64-year-old woman with differentiated thyroid cancer.

Lori Wirth, MD, a medical oncologist, reviews the case of a 64-year-old woman with differentiated thyroid cancer (DTC).

Results from a retrospective study found that patients with certain features were at a greater risk of recurrence of papillary thyroid cancer.

Francis P. Worden, MD, provides background on the COSMIC-311 study, highlighting the methods and design utilized.

In an interview with Targeted Oncology, Francis P. Worden, MD, discussed data from the COSMIC-311 study which support treatment with cabozantinib for patients with radioiodine-refractory differentiated thyroid cancer.

A trial comparing selpercatinib with cabozantinib or vandetanib led to greater benefit and favorable safety in the selpercatinib arm, supporting use of the selective RET inhibitor as first-line treatment for patients with advanced RET-mutant medullary thyroid cancer, according to interim data presented at the 2023 ESMO Congress.

Patients had longer median progression-free survival rates with anlotinib vs with placebo in a phase 2 trial, but overall survival data were still immature.

Warren C. Swegal, MD, discusses the safety and tolerability of tyrosine kinase inhibitors for patients with radioactive iodine–refractory differentiated thyroid cancer.

Marcia S. Brose, MD, PhD, FASCO, discusses the landscape of thyroid cancer by explaining the complexities and promising advancements seen in the space.

Warren C. Swegal, MD, discusses the role of cabozantinib (Cabometyx) for patients with radioactive iodine (RAI)–refractory differentiated thyroid cancer (DTC).

In an interview with Targeted Oncology, Marcia S. Brose, MD, PhD, FASCO discussed the impact of selpercatinib in thyroid cancer, and what to expect from the drug in the future.

Marcia S. Brose, MD, PhD, FASCO, discusses trials LIBRETTO program leading up to LIBRETTO-531.

During an interview with Targeted Oncology, Geoffrey Young, MD, PhD, discussed the impact of molecular testing, targeted therapies, and new approaches to surgical management of thyroid cancers.

According to Marcia Brose, MD, PhD, FASCO, interim findings from the phase 3 LIBRETTO-531 trial confirms the benefit of selpercatinib in patients with advanced, RET-mutant medullary thyroid cancer.

Investigators have shared final results from the first prospective study of a BRAK/MEK inhibitor combination in patients with advanced rare cancer, including anaplastic thyroid cancer.

Everett E. Vokes, MD, discusses the clinical application of next-generation sequencing for head and neck cancers, including thyroid cancers.

Yuri E. Nikiforov, MD, PhD, discusses improvements in diagnosis of thyroid cancer including the classification of noninvasive follicular thyroid neoplasm with papillary-like nuclear features.

In an interview with Targeted Oncology, Warren C. Swegal, MD, takes a deep dive into the radioactive iodine-refectory differentiated thyroid cancer treatment armamentarium, and predicts the role of key agents in the near future.

Warren Swegal, MD, explains how lenvatinib in currently used in the differentiated thyroid cancer landscape.

Though scientific advances have been encouraging in the thyroid cancer space, there is much more work to be done to figure out exactly how to tailor the right therapy, or combination of therapies, for individual patients.

Yuri E. Nikiforov, MD, PhD, discusses the over treatment of thyroid cancer and why the incidence of this disease has been increasing over the past few decades.

Yuri E. Nikiforov, MD, PhD, discusses the approach to treating noninvasive follicular thyroid neoplasm with papillary-like nuclear features, which is now classified distinctly from thyroid cancers.